Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

I'm Jason Zemansky. I'm one of the SMID-cap analysts here at BofA, and thank you for joining us on this -- our first day, second half of our Healthcare Conference in [ Veeva ], Las Vegas. I hope it's ...

All right, everybody. We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover pharma and biotech. And I'm pleased to ...

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE)-- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® ...

Cytokinetics Inc. CYTK shares are up on Tuesday as the company announced positive topline results from its pivotal Phase 3 ACACIA-HCM trial, which met both dual primary endpoints. The trial evaluated ...

Abstract: Sleep apnea-hypopnea syndrome (SAHS) seriously affects human sleep, so it is necessary to find the disease as early as possible. However, most of traditional models use convolutional neural ...

In the ACACIA-HCM trial, aficamten demonstrated a statistically significant improvement over placebo in both KCCQ-CSS (P =.021) and pVO2 (P =.003) at 36 weeks, with no new safety signals observed.

Objective: To establish the prevalence of chronotropic incompetence in a cohort of patients with chronic heart failure (CHF) taking modern medications for heart failure, and whether this affected ...

Introduction Identifying acute hypercapnic respiratory failure is crucial in the initial management of acute exacerbations of COPD. Guidelines recommend obtaining arterial blood samples but these are ...